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Targeted oncolytic poxviruses hold promise for the treatment of cancer. Arming these agents with immunostimulatory cytokines
(for example, granulocyte-monocyte colony-stimulating factor; GM-CSF) can potentially increase their efficacy and/or alter their
safety. However, due to species-specific differences in both human GM-CSF (hGM-CSF) activity and poxviruses immune avoidance
proteins, the impact of hGM-CSF expression from an oncolytic poxvirus cannot be adequately assessed in murine or rat tumor
models. We developed a rabbit tumor model to assess toxicology, pharmacodynamics, oncolytic efficacy and tumor-specific
immunity of hGM-CSF expressed from a targeted oncolytic poxvirus JX-963. Recombinant purified hGM-CSF protein stimulated a
leukocyte response in this model that paralleled effects of the protein in humans. JX-963 replication and targeting was highly tumor-
selective after i.v. administration, and intratumoral replication led to recurrent, delayed systemic viremia. Likewise, hGM-CSF was
expressed and released into the blood during JX-963 replication in tumors, but not in tumor-free animals. hGM-CSF expression from
JX-963 was associated with significant increases in neutrophil, monocyte and basophil concentrations in the peripheral blood.
Finally, tumor-specific cytotoxic T lymphocytes (CTL) were induced by the oncolytic poxvirus, and expression of hGM-CSF from the
virus enhanced both tumor-specific CTL and antitumoral efficacy. JX-963 had significant efficacy against both the primary liver
tumor as well as metastases; no significant organ toxicity was noted. This model holds promise for the evaluation of
immunostimulatory transgene-armed oncolytic poxviruses, and potentially other viral species.
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Introduction
Oncolytic viruses (virotherapy) kill cancer cells through
a novel mechanism-of-action; oncolysis has features of
both necrosis and apoptosis. Oncolytic virus replication
can be targeted to cancer cells specifically. Selective
intratumoral replication leads to virus multiplication,
lysis of the infected cancer cell and spread to adjacent and
distant cancer cells. In addition, these therapeutics can
kill through additional mechanisms including induction
of tumor-specific cytotoxic T lymphocytes (CTL), and
‘arming’ for expression of therapeutic transgene products.
Therefore, armed virotherapeutics have multiple attrac-
tive features needed in a novel cancer treatment platform.
Granulocyte-monocyte colony-stimulating factor (GM-
CSF) has shown great promise in strategies to induce
tumor-specific CTLs.
1 For this reason, the human GM-
CSF gene (hGM-CSF) has been engineered into several
oncolytic viruses including adenoviruses,
2 herpes viruses
3
and vaccinia.
4 Murine GM-CSF (mGM-CSF) expression
increased the injection site efficacy of a replication-selective
oncolytic adenovirus in immunodeficient mice following
intratumoral injection.
5 An attenuated oncolytic herpes
virus (HSV) expressing murine GM-CSF (mGM-CSF)
demonstrated tumor growth inhibition in mice at distant
sites following intratumoral injection; distant efficacy was
superior to that with a mGM-CSF  control virus. A hGM-
CSF-expressing vaccinia virus (JX-594) demonstrated
objective tumor responses following intratumoral injection
in patients with refractory cancers in the liver; responses
were demonstrated at both injection sites and in distant,
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6,7 JX-594 replicated, spread and was
released into the blood resulting in infection of distant
noninjected tumor sites; T-cell infiltrations and regressions
of distant skin metastases have also been demonstrated.
6,8
Similar findings were noted with another oncolytic
poxvirus, JX-963, in preclinical models.
9 In summary,
hGM-CSF-expressing oncolytic viruses hold potential for
cancer treatment.
A major hurdle for the development of these promising
therapeutics, however, is the lack of a validated animal
tumor model to assess the effects of hGM-CSF expression
from oncolytic poxviruses. For example, one problem is
that murine and hGM-CSF proteins have important
differences in their activities. mGM-CSF induces only
GM colonies, whereas hGM-CSF induces various types of
colonies including GM, eosinophil, mast cell, erythrocyte,
megakaryocyte, blast cell and mixed hemopoietic
colonies.
10 In addition, hGM-CSF itself is not fully active
in mice or rats.
11,12 Finally, a number of poxvirus immune
avoidance gene products are partially or completely
inactive in mice. We therefore sought to develop an
immunocompetent tumor model that had the following
features: (1) hGM-CSF had similar activity to that shown
in humans, (2) vaccinia replicated efficiently and (3)
vaccinia immune avoidance proteins were active. For these
studies we tested matched targeted vaccinia viruses with
hGM-CSF expression (JX-963) and without it (vvDD).
Result
Characterization of vvDD (without GM-CSF) and JX-963
(with GM-CSF) in vitro
The viruses in this study were generated from the Western
Reserve vaccinia virus-derived vvDD backbone with dele-
tions in both the thymidine kinase gene and the vaccinia
growth factor (vgf) gene; these two deletions resulted in
a significant increase in safety and cancer selectivity.
13
The vvDD expressing hGM-CSF under control of the
synthetic early-late promoter was designated JX-963.
7,9 As
was described previously,
2,7,9 JX-963 was constructed from
vvDD by insertion of hGM-CSF into the TK gene
(Supplemental Figure 1). The GM-CSF production from
a panel of four cancer cells was compared in vitro after
infection with vvDD, JX-963 or JX-594 infection (control
vaccinia expressing GM-CSF; GM-CSF inserted into
Wyeth strain vaccinia into disrupted TK region; Supple-
mental Table 1).
6 As was expected, no GM-CSF was
produced by vvDD, whereas both JX-963 and JX-594
produced GM-CSF from all cells at 24h postinfection. The
in vitro replication rates of vvDD and JX-963 showed no
significant difference (Supplemental Figure 2); JX-963
replication was significantly higher than that with JX-594
(approximately 10-fold higher at 72h; Po0.05).
Development and characterization of a novel VX2
rabbit liver cancer model for use with hGM-CSF-
expressing oncolytic poxviruses
An immunocompetent, orthotopic and spontaneously
metastasizing rabbit (New Zealand White; NZW) VX2
tumor model was established as follows. VX2 tumor
fragments (1mm
3) were implanted into hepatic paren-
chyma and the implantation site was subsequently
covered with Surgicel patch, which prevented initial
dissemination of tumor cells. Both primary tumor growth
and systemic metastases development and growth were
monitored by serial weekly CT scans. Reproducible
time-dependent development of multiple lung and liver
metastases (contralateral lobe) was demonstrated
(Figure 1a–d).
Pharmacokinetics and pharmacodynamics of
recombinant human GM-CSF protein in the NZW rabbit
The inbred rabbit was selected in this study as the in vivo
test species for efficacy and safety testing of JX-963 based
on literature references indicating that hGM-CSF has
biological activity in that species, as well as extensive
literature citations on the use of the rabbit for vaccinia
research.
13 However, there is no direct evidence on
hematological effect of recombinant human GM-CSF
protein (rhGM-CSF) in rabbit species. Therefore, in
response to a request from US FDA, we elected to
determine the effects of daily dosing with hGM-CSF
protein, at doses similar to those used in humans, on
subpopulations of WBC in the normal rabbit.
Serial hematological changes were observed after s.c.
injection (daily for 10 days, 40mgkg
 1) of rhGM-CSF in
these normal rabbits to determine hGM-CSF activity.
rhGM-CSF significantly increased the total WBC on
days 2, 4, 6 and 11 (Figure 2a). The transient decrease in
total WBC in the control group was presumably due
to daily blood sampling. On the WBC differential
analysis, absolute neutrophil, monocyte and basophil
concentrations were significantly increased (Figure 2b–d).
Plasma concentrations of hGM-CSF in samples taken
immediately before treatment (trough levels) on each of
the blood sampling days ranged from 12.3 to 37.8pgml
 1
(Supplemental Figure 3) indicating that prolonged
exposure (at least 24h) to hGM-CSF occurred as a
consequence of the daily subcutaneous administration.
These concentrations are similar to concentrations in
humans treated with rhGM-CSF. To our knowledge,
these results are the first report of the direct effect of
hGM-CSF protein on WBC populations in the rabbit
or any rodent. These results confirm similar pharmaco-
dynamic effects of hGM-CSF in NZW rabbits and
humans.
Biodistribution and pharmacodynamics of vvDD and
JX-963 after intravenous injection in VX2 rabbit tumor
model
vvDD (no hGM-CSF) or JX-963 (vvDD encoding hGM-
CSF) were administered i.v. to rabbits with VX2 primary
liver tumors and systemic metastases. The biodistribution
of vvDD and JX-963 were assessed at serial time points
(four rabbits per time point: two male, two female).
Tumor and normal organ tissue samples were harvested
and viral titers were assessed as described. Significant
increases and persistence of viral titers over time,
indicative of replication, were observed in tumor tissues
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Cancer Gene Therapyon days 1 22 after i.v. administration of vvDD or JX-963
(Figure 3a). Serum hGM-CSF was measured in normal,
tumor-free rabbits or in the VX2-bearing rabbit
model after i.v. injection of vvDD or JX-963. As shown
in Figure 3b, measurable hGM-CSF was detected in
serum obtained from VX2-bearing rabbits treated with
JX-963 (hGM-CSF expressing). However, hGM-CSF
was detected only at extremely low concentrations, or
was undetectable, in serum after i.v. administration in
tumor-free rabbits (Figure 3a) suggesting i.v. administration,
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Figure 1 VX2 intrahepatic tumor in inbred New Zealand Rabbit model. (a) Time dependent increase of VX2 hepatic mass determined by
CT. (b) Time dependent increase of pulmonary metastasis determined by CT. (c) Representative CT of primary hepatic mass (left, red arrow)
and lung metastasis (right, red arrow). (d) Representative gross image of primary hepatic mass (left) and histology of metastatic pulmonary
nodule (right).
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tumor-specific. As expected, vvDD did not lead to
detectable serum GM-CSF at doses even 10-fold higher
than that with JX-963 (data not shown).
Immune response parameters after intravenous injection
of vvDD and JX-963: induction of neutralizing
antibodies and tumor-targeting cytotoxic T lymphocytes
To assess the immune response against both the product
itself (neutralizing antibodies) and against the target
tumor (tumor-specific CTL), we evaluated these para-
meters after i.v. vvDD or JX-963. Neutralizing antibodies
to JX-963 became detectable as soon as 5 days after i.v.
injection and rose through day 18 (Supplemental Figure
4); a dose-response trend was notable (Po0.05 at days 8
and 18). We subsequently compared neutralizing anti-
body titers in day 18 serum after i.v. JX-963 or vvDD.
Serum antibody titers were not significantly different after
JX-963 or vvDD injection (data not shown).
For CTL assays against VX2 tumor cells, on in vitro
target cell assay had to be developed. VX2 tissues are
typically maintained by serial in vivo passage by intra-
muscular injection in rabbits; to our knowledge, VX2
cell lines have not been derived and perpetuated for
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Figure 3 Tumor-specific replication, biodistribution and serum granulocyte-monocyte colony-stimulating factor (GM-CSF) protein expression
after i.v. administration of JX-963 in the VX2 liver tumor model. (a) Biodistribution of vvDD and JX-963 in tumors vs normal organs over
time following intravenous injection. (b) hGM-CSF serum concentrations over time following intravenous injection of JX-963 in tumor-free and
VX2-bearing rabbits.
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Figure 2 Hematological effects of recombinant human granulocyte-monocyte colony-stimulating factor (hGM-CSF) protein in normal New
Zealand White (NZW) rabbits. The effect of serial rhGM-CSF protein s.c. on days 1–10 was studied including effects on blood concentrations of
(a) total WBC, (b) neutrophils, (c) monocytes, (d) basophils (* statistically significant difference vs control group).
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Cancer Gene Therapyin vitro passage. We generated VX2 single cell suspen-
sions by enzymatic treatment as described in the
methods section, and after eight passages cells were used
as in vitro target cells. Splenocytes were isolated from
VX2-bearing rabbits before and after multiple injec-
tions of i.v. phosphate-buffered saline (PBS), vvDD or
JX-963. vvDD injection led to a significant increase in
VX2-targeting CTL vs PBS as predicted (Figure 4a; Po
0.05). In addition, JX-963 CTL induction was signifi-
cantly higher than with vvDD, presumably due to hGM-
CSF expression within the tumor milieu (Figure 4b;
Po 0.05).
Efficacy of vvDD and JX-963 against primary and
metastatic tumors following intravenous administration
Antitumoral efficacy against primary and metastatic
tumor foci was evaluated by serial chest and abdominal
CT scanning in this VX2 tumor model (see above). As
previously described, vvDD had significant efficacy in
the VX2 model at a dose of 3 10
8p.f.u.kg
 1 i.v.
4
To determine whether the expression of hGM-CSF from
vvDD (JX-963) led to improved efficacy, we administered
animals with a subtherapeutic dose of i.v. vvDD
(3 10
7p.f.u.kg
 1). Of note, diffuse microscopic metas-
tases were present in control animals killed at the same
time as treatment was started; these metastases were not
detectable by CT at the time. Both vvDD and JX-963 had
efficacy against the large established primary tumor
within the liver (Figure 5a; Po0.05 vs PBS); by week 8,
JX-963 efficacy was significantly greater than that with
vvDD. Both vvDD and JX-963 were effective at prevent-
ing the outgrowth of CT-detectable tumor metastases in
liver and lung (Figure 4b; Po0.05 vs PBS). JX-963 was
able to completely prevent the outgrowth of detectable
lung or liver metastases in these animals (Figure 5b;
Po0.05 vs vvDD). Rabbits treated with PBS or this
relatively low dose of vvDD had a median survival of 7 or
9 weeks, respectively, vs 14 weeks in the JX-963 injected
rabbit group (Figure 5c; Po0.05). JX-963-treated rabbits
also gained weight whereas PBS treated animals lost
weight (data not shown). Therefore, the vvDD oncolytic
vaccinia virus had systemic efficacy against both large
established primary liver tumors and systemic microme-
tastases, and arming with hGM-CSF further increased
systemic anticancer efficacy and survival.
GLP toxicology study of i.v. JX-963 in NZW rabbits
To prepare for a phase I clinical trial with JX-963, we
performed a toxicity study with i.v. JX-963 under Good
Laboratory Practice (GLP) guidelines. Doses were
3 10
7p.f.u.kg
 1 and 1 10
8p.f.u.kg
 1 as either once
or thrice weekly doses. In a subsequent non-GLP study, a
dose of 1 10
9p.f.u.kg
 1 in the same treatment regimens
was evaluated. These doses were up to 30-fold higher than
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Figure 5 Antitumoral efficacy of i.v. vvDD and JX-963 in VX2 tumor model. (a) Growth curves of primary hepatic tumors in groups treated i.v.
with vvDD, JX-963 or phosphate-buffered saline (PBS; control). (b) Antitumoral efficacy against lung metastases (week 8 after tumor
implantation) for groups treated i.v. with vvDD, JX-963 or PBS (control). (c) Kaplan–Meier survival curves for overall survival of treatment groups.
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Cancer Gene Therapyefficacious doses in tumor-bearing animals. No animal
deaths were reported after either single-dose or multiple-
dose i.v. injection. Only at the highest dose level, transient
rapid breathing and inactivity was noted postdosing but
resolved within 1h; lower dose animals had no change in
activity. Mild-dose-related decreases in body weights were
noted following dosing, but weight gain resumed after
2 weeks in all cases. Changes in hematology included
transient monocytosis and thrombocytosis in treated
animals. No normal tissue toxicities were evident on
histopathology analyses even though virus replication-
based quantitative PCR was observed transiently in some
normal tissues for 1–5 days. The only treatment-related
histopathology findings consisted of perivascular mono-
cytic inflammation at injection sites (data not shown).
Discussion
Cody et al.
14 reported that dendritic cells could be
generated in vitro from rabbit bone marrow cells using a
combination of hGM-CSF, interleukin-4 and LPS,
indicating cross-species reactivity. Human GM-CSF given
intraperitoneally to neonatal rabbits increased blood
eosinophil and granulocyte counts, an effect similar to
that reported after administration of hGM-CSF to
humans.
15 Taken together, these papers indicate that
hGM-CSF has cross-species reactivities in the rabbit that
are qualitatively similar to some of those reported in the
human for this multilineage hematopoietin.
16 However,
neither paper provided quantitative data on the effects of
hGM-CSF on populations of WBC in the rabbit that
could be compared with those reported for the human.
We sought to develop an immunocompetent tumor model
that had the following features: (1) hGM-CSF had similar
activity to that shown in humans, (2) vaccinia replicated
efficiently and (3) vaccinia immune avoidance proteins were
active. As poxviruses replicate efficiently in NZW rabbits,
and many immunomodulatory poxvirus proteins are active
in rabbits, we elected to develop an orthotopic, immuno-
competent rabbit tumor model. For these studies we tested
matched targeted vaccinia viruses with hGM-CSF expres-
sion (JX-963) and without it (vvDD). In this study, for the
first time to our knowledge, we demonstrated direct
hematologic effects of hGM-CSF protein in rabbits that
parallel effects in humans. Significant increases were noted
in neutrophils and monocytes. vvDD and JX-963 replication
and targeting were highly tumor-selective after i.v. admin-
istration, and intratumoral replication led to recurrent,
delayed systemic viremia. The reason for initial accumula-
tion of JX-963 into tumor environment after i.v. adminis-
tration may be due to leaky tumor microvasculature as we
have observed high dose of virus in tumor tissues after either
vvDD or JX-963 administration.
Likewise, hGM-CSF was expressed and released into
the blood during JX-963 replication in tumors, but not in
tumor-free animals. hGM-CSF expression from JX-963
was associated with significant increases in neutrophil,
monocyte and basophil concentrations in the peripheral
blood. Finally, tumor-specific CTL were induced by the
oncolytic poxvirus, and expression of hGM-CSF from the
virus enhanced both tumor-specific CTL and antitumoral
efficacy. JX-963 had significant efficacy against both the
primary liver tumor as well as metastases; no significant
organ toxicity was noted. This model holds promise for
the evaluation of immunostimulatory transgene-armed
oncolytic poxviruses, and potentially other viral species.
Animal tumor models with better predictive value should
lead to improved optimization of these products, and as a
result better clinical benefits for patients.
Methods
Viruses
The construction of vvDD was described previously;
13
vvDD is a TK  and VGF  engineered Western Reserve
strain vaccinia virus. JX-963, which expresses hGM-CSF
from the disrupted TK gene region under control of the
synthetic early-late promoter, was described previously.
6
Rabbit VX2 tumor model studies
VX2 tumors were grown in the muscle of inbred NZW
rabbits (Samtako, Oh-San, Korea) and cells from a
1–2mm
3 fragment of tumor were dissociated, resuspended
in 0.1ml normal saline and injected via a 21-gauge needle
beneath the liver capsule. The injection site was covered
with a Surgicel patch followed by a purse-string tie to
prevent release of VX2 cells from the injection site.
Cytotoxic T-lymphocyte study
Isolated VX2 cells were used for target cells, and
splenocytes isolated from VX2-bearing rabbits after
JX-963, vvDD or PPS multiple injection ( 3) were used
for effector cells. VX2 cell lines were isolated from VX2
tissues enzymatically (collagenase 0.01 %þproteas 0.1 %
O/N at 4C), and maintained in vitro with Dulbecco’s
modified Eagle’s medium with 10 % fetal bovine serum
(FBS) for 8 passages. However VX2 cells can not be
grown after storage at  801C, and we could not keep this
study under more controlled environment. For isolation
of splenocytes, spleens were harvested at the time of
killing (1 week after i.v. dosing weekly for 3 weeks) and
fractionated through a 70-mm nylon cell strainer. After
red blood cell lysis, the splenocyte pool was suspended
in RPMI 1640 medium with 90 % FBS, and then stored
at  801C before CTL measurement. CTL activity was
measured by fluorescence-activated cell sorting using the
ACT1 assay (Cell Technology, Mountain View, CA).
Effects of hGM-CSF in rabbit model
Leukokine (hGM-CSF recombinant protein; LG Life-
science, Seoul, Korea) or control solution was adminis-
tered s.c. daily for 10 days (days 1–10) to rabbits.
Measurement of serum antibodies to JX-963 or vvDD
The titer of antivaccinia NAb was determined by
measuring the ability of the serum to protect A2780 cells
from death caused by viral infection. Diluted serum
Oncolytic poxvirus for systemic cancer treatment in rabbits
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the mixture was inoculated onto an A2780 cell monolayer.
Cell viability was measured 3 days after inoculation by
means of colorimetric assay (CCK-8; Dojindo, Inc.,
Kumamoto, Japan).
Statistical analyses
Kaplan–Meier curves were compared using the general-
ized Wilcoxin test. Tumor response rates and metastasis-
free rates were compared with Fisher’s exact test.
Live rabbits (3 rabbits among 5) on week 14 were
simply killed at this point. Tumor size was monitored by
CT every 1–2 weeks. CT screening at 10 week was not
included as we did not anticipate that JX-963-injected
rabbits can live for more than 14 weeks. The number of
animals are different between groups; four rabbits in each
control and vvDD group and five rabbits in JX-963
group. We included many control data as we did a lot of
control vx2 model in a separate study. In most cases done
in different time, control rabbits died within 5–9 weeks
without significant deviation.
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